Study S002234

Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07065383
Acronym: Re-CHARM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 60
Start: 2025-08-01
Primary completion: 2028-07-31
Lead sponsor: University of Aberdeen
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Semaglutide administration plus dietary counselling and physical activity encouragement; DRUG:Semaglutide plus a personalised and supervised program of resistance and endurance training
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

1H-magnetic resonance spectroscopy [From enrollment to the end of treatment at the end of 12 weeks]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008068	Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff AM, The New England journal of medicine	2023	Randomized trial	PMID 37952131 DOI	registry reference BACKGROUND:37952131
R0010300	Epicardial adipose tissue in contemporary cardiology. Iacobellis G, Nature reviews. Cardiology	2022	Narrative review	PMID 35296869 DOI	registry reference BACKGROUND:35296869
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0025356	Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Blundell J, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28266779 DOI	registry reference BACKGROUND:28266779
R0022278	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27633186 DOI	registry reference BACKGROUND:27633186